参考文献:1. Hanahan, D, Weinberg, RA (2011) Hallmarks of cancer: the next generation. Cell 144: pp. 646-74 2011.02.013" target="_blank" title="It opens in new window">CrossRef 2. Kuper, H, Adami, HO, Trichopoulos, D (2000) Infections as a major preventable cause of human cancer. J Intern Med 248: pp. 171-83 2796.2000.00742.x" target="_blank" title="It opens in new window">CrossRef 3. Fridman, WH (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: pp. 298-306 245" target="_blank" title="It opens in new window">CrossRef 4. Correa, P (1992) Human gastric carcinogenesis: a multistep and multifactorial process鈥揻irst American cancer society award lecture on cancer epidemiology and prevention. Cancer Res 52: pp. 6735-40 5. IARC Monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. In: Internatioanl Agency for Research on Cancer Moonograph 61, Lyon, France. 1994;177鈥?40. 6. Houghton, J, Wang, TC (2005) Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 128: pp. 1567-78 2005.03.037" target="_blank" title="It opens in new window">CrossRef 7. Ferlay, J (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: pp. 2893-917 2/ijc.25516" target="_blank" title="It opens in new window">CrossRef 8. Bang, YJ (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: pp. 687-97 21-X" target="_blank" title="It opens in new window">CrossRef Comprehensive molecular characteristics of gastric adenocarcinoma. Nature 513: pp. 202-9 CrossRef 9. Hanahan, D, Weinberg, RA (2000) The hallmarks of cancer. Cell 100: pp. 57-70 2-8674(00)81683-9" target="_blank" title="It opens in new window">CrossRef 10. Bobryshev, YV (2009) Dendritic cell-associated immune inflammation of cardiac mucosa: a possible factor in the formation of Barrett鈥檚 esophagus. J Gastrointest Surg 13: pp. 442-50 CrossRef 11. Zingg, U (2010) Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol 36: pp. 670-7 2010.05.012" target="_blank" title="It opens in new window">CrossRef 12. Wang F, ZS Lv, YK Fu. Nonsteroidal anti-inflammatory drugs and esophageal inflammation鈥揃arrett鈥檚 esophagus鈥揳denocarcinoma sequence: a meta-analysis. Dis Esophagus. 2011;24(5):318鈥?4. 13. Nguyen, GH (2010) Inflammatory and microRNA gene expression as prognostic classifier of Barrett鈥檚-associated esophageal adenocarcinoma. Clin Cancer Res 16: pp. 5824-34 2.CCR-10-1110" target="_blank" title="It opens in new window">CrossRef 14. Marshall, BJ, Warren, JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: pp. 1311-5 CrossRef 15. Lundin, BS (2007) The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol 125: pp. 205-13 2007.07.011" target="_blank" title="It opens in new window">CrossRef 16. Enarsson, K (2006) Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol 121: pp. 358-68 2006.07.002" target="_blank" title="It opens in new window">CrossRef 17. Kao, JY (2010) Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology 138: pp. 1046-54 2009.11.043" target="_blank" title="It opens in new window">CrossRef 18. Szkaradkiewicz, A (2010) Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol 2010: pp. 901564 2010/901564" target="_blank" title="It opens in new window">CrossRef 19. El-Omar, EM (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124: pp. 1193-201 CrossRef 20. Figueiredo, C (2002) Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94: pp. 1680-7 22.1680" target="_blank" title="It opens in new window">CrossRef 21. Lee, HE (2008) Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 99: pp. 1704-11 CrossRef 22. Melero, I (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11: pp. 509-24 2014.111" target="_blank" title="It opens in new window">CrossRef 23. Ochiai, T (1983) Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother 14: pp. 167-71 205355" target="_blank" title="It opens in new window">CrossRef 24. Popiela, T (2004) Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 7: pp. 240-5 20-004-0299-y" target="_blank" title="It opens in new window">CrossRef 25. Sato, Y (2004) A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. J Immunother 27: pp. 394-7 2371-200409000-00008" target="_blank" title="It opens in new window">CrossRef 26. Turcotte, S (2013) Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol 191: pp. 2217-25 CrossRef 27. Kono, K (2002) Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 8: pp. 1767-71 28. Jiang, J (2006) Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26: pp. 2237-42 29. Shi, L (2012) Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 61: pp. 2251-9 262-012-1289-2" target="_blank" title="It opens in new window">CrossRef 30. Fujiwara, S (2012) Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother 35: pp. 513-21 2619cb4" target="_blank" title="It opens in new window">CrossRef 31. Kono, K (2002) Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8: pp. 3394-400 32. Sadanaga, N (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7: pp. 2277-84 33. Tanaka, H (2012) Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer Res 32: pp. 3427-33 34. Ajani, JA (2006) An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106: pp. 1908-16 2/cncr.21814" target="_blank" title="It opens in new window">CrossRef 35. Sato, Y (2003) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: pp. 802-8 2003.tb01522.x" target="_blank" title="It opens in new window">CrossRef 36. Iwahashi, M (2010) Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 101: pp. 2510-7 2010.01732.x" target="_blank" title="It opens in new window">CrossRef 37. Kono, K (2012) Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 10: pp. 141 CrossRef 38. Kageyama, S (2013) Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med 11: pp. 246 246" target="_blank" title="It opens in new window">CrossRef 39. Ohtsu, A (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: pp. 3968-76 200/JCO.2011.36.2236" target="_blank" title="It opens in new window">CrossRef 40. Fuchs, CS (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383: pp. 31-9 CrossRef 41. Wilke, H (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15: pp. 1224-35 2045(14)70420-6" target="_blank" title="It opens in new window">CrossRef 42. Masuzawa, T (2012) Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol 41: pp. 1297-304 43. Higashihara, Y (2014) Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol 44: pp. 662-8 44. Jeung, HC (2008) Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 19: pp. 520-6 CrossRef 45. Park, JJ (2010) B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116: pp. 1291-8 2/blood-2010-01-265975" target="_blank" title="It opens in new window">CrossRef 46. Butte, MJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: pp. 111-22 2007.05.016" target="_blank" title="It opens in new window">CrossRef 47. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711鈥?3 48. Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455鈥?5 49. Sun, J (2007) PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 69: pp. 19-27 2006.00701.x" target="_blank" title="It opens in new window">CrossRef 50. Muro K, Bang Y-J, Shankaran V, Geva R, Catenacci D, Gupta S, Eder J, Berger R, Gonzalez E, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford J, Cheng J, Koshiji M, Chung HC, Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol 2015. 33:3; abstr 3. 51. Herbst, RS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: pp. 563-7 CrossRef 52. Robbins, PF (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19: pp. 747-52 CrossRef